186 related articles for article (PubMed ID: 30130452)
1. Update of humanized animal disease models in studying Graft-versus-host disease.
Huang F; Cao FL; Zheng SG
Hum Vaccin Immunother; 2018; 14(11):2618-2623. PubMed ID: 30130452
[TBL] [Abstract][Full Text] [Related]
2. Increased splenic human CD4
Geraghty NJ; Belfiore L; Adhikary SR; Alexander SI; Sluyter R; Watson D
Transpl Immunol; 2019 Jun; 54():38-46. PubMed ID: 30743002
[TBL] [Abstract][Full Text] [Related]
3. Tolerance induction permits the development of graft-versus-host disease: donor-mediated attack following small bowel transplantation in mixed chimeras.
Morrissey NJ; Blom D; Ryan CK; Fisher T; Bronsther O; Orloff MS
Transpl Immunol; 1999 Mar; 7(1):19-25. PubMed ID: 10375074
[TBL] [Abstract][Full Text] [Related]
4. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
5. PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Ry
Burger DR; Parker Y; Guinta K; Lindner D
Biol Blood Marrow Transplant; 2018 Feb; 24(2):260-266. PubMed ID: 29128556
[TBL] [Abstract][Full Text] [Related]
6. Proliferation-based T-cell selection for immunotherapy and graft-versus-host-disease prophylaxis in the context of bone marrow transplantation.
Pachnio A; Dietrich S; Klapper W; Humpe A; Schwake M; Sedlacek R; Gramatzki M; Beck C
Bone Marrow Transplant; 2006 Jul; 38(2):157-67. PubMed ID: 16820783
[TBL] [Abstract][Full Text] [Related]
7. Prevention of acute graft-versus-host disease by humanized anti-CD26 monoclonal antibody.
Hatano R; Ohnuma K; Yamamoto J; Dang NH; Yamada T; Morimoto C
Br J Haematol; 2013 Jul; 162(2):263-77. PubMed ID: 23692598
[TBL] [Abstract][Full Text] [Related]
8. Prevention of lethal graft-versus-host disease following allogeneic bone marrow transplantation in mice by short course administration of LF 08-0299.
Annat J; Churaqui E; Dutartre P; Bruley-Rosset M
Transplantation; 1996 Sep; 62(6):721-9. PubMed ID: 8824467
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
Schwinghammer TL; Bloom EJ
Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
[TBL] [Abstract][Full Text] [Related]
10. Hematopoietic chimerism, tolerance induction and graft-versus-host disease: considerations for composite tissue transfer.
Exner BG; Acholonu I; Ildstad ST
Transplant Proc; 1998 Sep; 30(6):2718-20. PubMed ID: 9745553
[No Abstract] [Full Text] [Related]
11. Suppression of graft-versus-host disease and retention of graft-versus-tumour reaction by murine genetically engineered dendritic cells following bone marrow transplantation.
Huang Y; Feng S; Xu Y; Chen W; Wang S; Li D; Li Z; Lu Q; Pan X; Xu K
Mol Med Rep; 2015 May; 11(5):3820-7. PubMed ID: 25529231
[TBL] [Abstract][Full Text] [Related]
12. The P2X7 receptor antagonist Brilliant Blue G reduces serum human interferon-γ in a humanized mouse model of graft-versus-host disease.
Geraghty NJ; Belfiore L; Ly D; Adhikary SR; Fuller SJ; Varikatt W; Sanderson-Smith ML; Sluyter V; Alexander SI; Sluyter R; Watson D
Clin Exp Immunol; 2017 Oct; 190(1):79-95. PubMed ID: 28665482
[TBL] [Abstract][Full Text] [Related]
13. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
[TBL] [Abstract][Full Text] [Related]
14. Animal models of acute and chronic graft-versus-host disease.
Hakim F; Fowler DH; Shearer GM; Gress RE
Curr Protoc Immunol; 2001 May; Chapter 4():Unit 4.3. PubMed ID: 18432794
[TBL] [Abstract][Full Text] [Related]
15. Effective treatment against severe graft-versus-host disease with allele-specific anti-HLA monoclonal antibody in a humanized mouse model.
Nakauchi Y; Yamazaki S; Napier SC; Usui J; Ota Y; Takahashi S; Watanabe N; Nakauchi H
Exp Hematol; 2015 Feb; 43(2):79-88.e1-4. PubMed ID: 25448490
[TBL] [Abstract][Full Text] [Related]
16. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease.
Chan GW; Gorgun G; Miller KB; Foss FM
Biol Blood Marrow Transplant; 2003 Mar; 9(3):170-6. PubMed ID: 12652467
[TBL] [Abstract][Full Text] [Related]
17. Immunological defects after suicide gene therapy of experimental graft-versus-host disease.
Cohen JL; Lacroix-Desmazes S; Charlotte F; Lejeune L; Martin PJ; Klatzmann D; Boyer O
Hum Gene Ther; 1999 Nov; 10(16):2701-7. PubMed ID: 10566898
[TBL] [Abstract][Full Text] [Related]
18. Is chronic graft versus host disease an autoimmune disease?
Parkman R
Curr Opin Immunol; 1993 Oct; 5(5):800-3. PubMed ID: 8240743
[TBL] [Abstract][Full Text] [Related]
19. Graft-versus-host disease after marrow transplantation.
Storb R
Prog Clin Biol Res; 1986; 224():139-57. PubMed ID: 3540990
[TBL] [Abstract][Full Text] [Related]
20. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation.
Dey BR; McAfee S; Colby C; Sackstein R; Saidman S; Tarbell N; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2003 May; 9(5):320-9. PubMed ID: 12766882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
